PharmOptima appoints business development director

Ophthalmology specialist hires Rick Coulon

PharmOptima, a US contract research organisation (CRO) with expertise in conducting drug metabolism and pharmacokinetic (DMPK) studies for ophthalmology products, has appointed Rick Coulon as director of business development.

Coulon has more than 20 years of sales, marketing and business development experience within the pharmaceutical industry. Although his background includes a broad list of therapeutic specialities, his strength is in ocular drug development.

Coulon has previously worked at Ciba Vision (Novartis), Akorn, Mallinckrodt Pharmaceuticals, Stonebridge Pharma (GSK), Auriga Laboratories and CCG Partners.

You may also like

Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development

Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder

The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development

Researchers identify early signs of Parkinson's in the blood

Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Research & Development

iXCells and Rosebud Biosciences pair up to advance organoid-based models for rare diseases

The expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses, meeting growing demand for scalable, patient-relevant human models to support translational decision-making in drug development
Subscribe now